Trial Profile
Non-Interventional Study Evaluating The Safety and Efficacy In Patients Receiving New PegIntron Pen for Hepatitis C.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 26 Apr 2011 New trial record